文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗特应性皮炎患者感染风险:随机对照试验荟萃分析

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.
PubMed 文献 · J Am Acad Dermatol · 2017-10-04

该荟萃分析纳入4篇文献中的8项随机对照试验、共2706例中重度特应性皮炎患者,随访4至52周。与安慰剂相比,度普利尤单抗降低皮肤感染风险(RR 0.54,95%CI 0.42-0.70)及疱疹性湿疹风险(OR 0.34,95%CI 0.14-0.84),而总体疱疹病毒感染与总体感染无显著关联。

要点

  • 度普利尤单抗可降低中重度AD患者皮肤感染风险。
  • 度普利尤单抗可降低疱疹性湿疹发生风险。
  • 总体疱疹病毒感染及总体感染风险未见显著变化。

核心结论

  • 度普利尤单抗与中重度AD成人皮肤感染和疱疹性湿疹发生率降低相关。
  • 该关联机制尚不明确,可能与其改善AD严重程度有关。
  • 度普利尤单抗靶向白细胞介素4和白细胞介素13,似可显著降低皮肤感染与疱疹性湿疹风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed数据库纳入度普利尤单抗治疗AD的随机对照试验。
  • 共纳入4篇文献中的8项随机对照试验,2706例参与者,随访时间4至52周。
  • 皮肤感染、疱疹病毒感染、总体感染与寄生虫侵染采用二分类随机效应荟萃分析计算RR及95%CI。
  • 疱疹性湿疹分析采用Peto比值比。

主要发现

  • 汇总所有给药方案与随访时间,度普利尤单抗对比安慰剂的皮肤感染RR为0.54(95%CI 0.42-0.70)。
  • 疱疹性湿疹的OR为0.34(95%CI 0.14-0.84)。
  • 总体疱疹病毒感染无显著关联(RR 1.16,95%CI 0.78-1.74)。
  • 总体感染无显著关联(RR 0.98,95%CI 0.83-1.16)。

临床怎么用

  • 对中重度AD成人使用度普利尤单抗时,可预期皮肤感染及疱疹性湿疹风险下降。
  • 仍需关注总体疱疹病毒感染与总体感染风险,其未见显著下降。

局限性

  • 多数试验随访时间较短。
  • 迄今接受度普利尤单抗治疗的患者数量相对较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is characterized by skin barrier defects, T helper type 2 cell activation, and increased risk for cutaneous and extracutaneous infections. In clinical trials, dupilumab appeared to decrease rates of skin infections in AD. OBJECTIVE: We aimed to determine the impact of dupilumab on rates of skin and other infections in patients with moderate-to-severe AD. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials of dupilumab for AD. We searched the PubMed database for relevant studies. Risk ratios (RRs) and 95% confidence intervals (CIs) for skin infections, herpesvirus infections, and overall infections and infestations were calculated for dupilumab compared with for placebo by using binary random effects meta-analysis. For the analysis of eczema herpeticum, Peto odds ratios were calculated. RESULTS: Eight randomized controlled trials in 4 publications with 2706 participants were included, with follow-up time ranging from 4 to 52 weeks. Meta-analysis including all dosing schedules and follow-up times showed a RR of skin infection of 0.54 (95% CI, 0.42-0.70) and an odds ratio of eczema herpeticum of 0.34 (95% CI, 0.14-0.84) for dupilumab compared with placebo. No significant association was found for dupilumab with overall herpesvirus infections (RR, 1.16; 95% CI, 0.78-1.74) and overall infections (RR, 0.98; 95% CI, 0.83-1.16). LIMITATIONS: Our analysis is limited by the short follow-up time in most trials and the relatively low number of patients treated with dupilumab to date. CONCLUSIONS: Dupilumab is associated with a decreased incidence of skin infections and eczema herpeticum in adults with moderate-to-severe AD. The mechanism underlying this association is uncertain but is likely related to improvement in AD severity. Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, appears to significantly decrease the risk for skin infections and eczema herpeticum in adults with moderate-to-severe AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2017. PMID: 28987493. doi:10.1016/j.jaad.2017.09.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。